Advertisement

Ads Placeholder
Loading...

Memphasys Limited

MEM.AXASX
Healthcare
Biotechnology
$0.004
$-0.00(-11.11%)
Australian Market opens in 2h 36m

Memphasys Limited Fundamental Analysis

Memphasys Limited (MEM.AX) shows moderate financial fundamentals with a PE ratio of -2.22, profit margin of -20.16%, and ROE of -91.88%. The company generates $0.0B in annual revenue with moderate year-over-year growth of 7.78%.

Key Strengths

PEG Ratio-0.02

Areas of Concern

ROE-91.88%
Operating Margin-16.64%
Cash Position4.84%
Current Ratio0.14
We analyze MEM.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1586.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1586.9/100

We analyze MEM.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

MEM.AX struggles to generate sufficient returns from assets.

ROA > 10%
-41.28%

Valuation Score

Excellent

MEM.AX trades at attractive valuation levels.

PE < 25
-2.22
PEG Ratio < 2
-0.02

Growth Score

Excellent

MEM.AX delivers strong and consistent growth momentum.

Revenue Growth > 5%
7.78%
EPS Growth > 10%
21.05%

Financial Health Score

Weak

MEM.AX carries high financial risk with limited liquidity.

Debt/Equity < 1
1.15
Current Ratio > 1
0.14

Profitability Score

Weak

MEM.AX struggles to sustain strong margins.

ROE > 15%
-9188.48%
Net Margin ≥ 15%
-20.16%
Positive Free Cash Flow
No

Key Financial Metrics

Is MEM.AX Expensive or Cheap?

P/E Ratio

MEM.AX trades at -2.22 times earnings. This suggests potential undervaluation.

-2.22

PEG Ratio

When adjusting for growth, MEM.AX's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values Memphasys Limited at 2.38 times its book value. This may indicate undervaluation.

2.38

EV/EBITDA

Enterprise value stands at -3.08 times EBITDA. This is generally considered low.

-3.08

How Well Does MEM.AX Make Money?

Net Profit Margin

For every $100 in sales, Memphasys Limited keeps $-20.16 as profit after all expenses.

-20.16%

Operating Margin

Core operations generate -16.64 in profit for every $100 in revenue, before interest and taxes.

-16.64%

ROE

Management delivers $-91.88 in profit for every $100 of shareholder equity.

-91.88%

ROA

Memphasys Limited generates $-41.28 in profit for every $100 in assets, demonstrating efficient asset deployment.

-41.28%

Following the Money - Real Cash Generation

Operating Cash Flow

Memphasys Limited generates limited operating cash flow of $-3.97M, signaling weaker underlying cash strength.

$-3.97M

Free Cash Flow

Memphasys Limited generates weak or negative free cash flow of $-3.97M, restricting financial flexibility.

$-3.97M

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

MEM.AX converts -23.17% of its market value into free cash.

-23.17%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.22

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.38

vs 25 benchmark

P/S Ratio

Price to sales ratio

59.88

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.15

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.14

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.92

vs 25 benchmark

ROA

Return on assets percentage

-0.41

vs 25 benchmark

ROCE

Return on capital employed

-0.83

vs 25 benchmark

How MEM.AX Stacks Against Its Sector Peers

MetricMEM.AX ValueSector AveragePerformance
P/E Ratio-2.2228.45 Better (Cheaper)
ROE-91.88%763.00% Weak
Net Margin-2015.96%-45265.00% (disorted) Weak
Debt/Equity1.150.34 Weak (High Leverage)
Current Ratio0.142795.60 Weak Liquidity
ROA-41.28%-16588.00% (disorted) Weak

MEM.AX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Memphasys Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

2.14%

Industry Style: Defensive, Growth, Innovation

Growing

FCF CAGR

-550.15%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ